|Other names||FK-780; recombinant human insulin-like growth factor-1; rhIGF-1; somatomedin-1|
|Main uses||Growth failure due to primary insulin-like growth factor-I deficiency|
|Side effects||Headache, low blood sugar, vomiting, lump at the site of injection, middle ear infection|
|Typical dose||0.04 to 0.12 mg/kg BID|
|Elimination half-life||5.8 hours|
|Chemical and physical data|
|Molar mass||7648.71 g·mol−1|
Mecasermin, sold under the brand name Increlex, is medication used to treat growth failure in children due to primary insulin-like growth factor-I deficiency or lack of the gene for growth hormone. It is also being look at for amyotrophic lateral sclerosis. It is given by injection under the skin.
Common side effects include headache, low blood sugar, vomiting, lump at the site of injection, and middle ear infection. Other side effects may include enlarged tonsils, intracranial hypertension, and slipped capital femoral epiphysis. It is a recombinant form of human insulin-like growth factor-1 (rhIGF-1).
Mecasermin was approved for medical use in the United States in 2005 and Europe in 2007. In the United States 400 mg costs about 54,000 USD as of 2021. This amount in the United Kingdom costs the NHS about £24,000.
It may be used in those 2 to 18 years old.
It is started at 0.04 mg/kg twice per day and may be increased up to 0.12 mg/kg twice per day.
A related medication is mecasermin rinfabate (brand name Iplex), which is a combination of mecasermin (rhIGF-1), insulin-like growth factor binding protein-3 (IGFBP-3), and insulin-like growth factor binding protein acid labile subunit (IGFALS) as a ternary complex. The complex serves to prolong the action of mecasermin in the human body; the half-life of mecasermin when provided as this complex is 13.4 hours in individuals with severe primary IGF-1 deficiency.
- "Mecasermin Monograph for Professionals". Drugs.com. Archived from the original on 6 March 2021. Retrieved 14 November 2021.
- "Increlex". Archived from the original on 14 November 2021. Retrieved 15 November 2021.
- "INCRELEX® (mecasermin [rDNA origin] injection) Highlights of Prescribing Information" (PDF). U.S. Food and Drug Administration. Archived (PDF) from the original on 2021-04-03. Retrieved 2020-08-23.
- "Increlex Prices, Coupons & Patient Assistance Programs". Drugs.com. Retrieved 15 November 2021.
- "Mecasermin". NICE. Archived from the original on 15 November 2021. Retrieved 15 November 2021.
- "IPLEXTM (mecasermin rinfabate [rDNA origin] injection) Package Insert" (PDF). U.S. Food and Drug Administration. Archived (PDF) from the original on 2020-10-30. Retrieved 2020-08-23.